Selected research
Industry Research
AI In Drug Development Industry Research Report 2026
Market perspective
The global AI In Drug Development market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the AI In Drug Development market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the AI In Drug Development market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the AI In Drug Development market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of AI In Drug Development include Pfizer, AstraZeneca, Johnson & Johnson, Novartis, Sanofi, Roche, Insilico Medicine, Exscientia and BenevolentAI, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global AI In Drug Development market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to AI In Drug Development.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
AI In Drug Development Market by Company
Pfizer
AstraZeneca
Johnson & Johnson
Novartis
Sanofi
Roche
Insilico Medicine
Exscientia
BenevolentAI
Recursion Pharmaceuticals
Atomwise
Isomorphic Labs
XtalPi
Deep Genomics
Relay Therapeutics
AI In Drug Development Segment by Type
Software
Services
AI In Drug Development Segment by Application
Biopharmaceuticals
Synthetic Pharmaceuticals
Others
AI In Drug Development Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AI In Drug Development market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of AI In Drug Development and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AI In Drug Development.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of AI In Drug Development companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Software
- Services
Applications
- Biopharmaceuticals
- Synthetic Pharmaceuticals
- Others
Companies covered
- Pfizer
- AstraZeneca
- Johnson & Johnson
- Novartis
- Sanofi
- Roche
- Insilico Medicine
- Exscientia
- BenevolentAI
- Recursion Pharmaceuticals
- Atomwise
- Isomorphic Labs
- XtalPi
- Deep Genomics
- Relay Therapeutics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 AI In Drug Development by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Software
- 2.2.3 Services
- 2.3 AI In Drug Development by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Biopharmaceuticals
- 2.3.3 Synthetic Pharmaceuticals
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 AI In Drug Development Breakdown Data by Type
- 3.1 Global AI In Drug Development Historic Market Size by Type (2021-2026)
- 3.2 Global AI In Drug Development Forecasted Market Size by Type (2027-2032)
4 AI In Drug Development Breakdown Data by Application
- 4.1 Global AI In Drug Development Historic Market Size by Application (2021-2026)
- 4.2 Global AI In Drug Development Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global AI In Drug Development Market Perspective (2021-2032)
- 5.2 Global AI In Drug Development Growth Trends by Region
- 5.2.1 Global AI In Drug Development Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 AI In Drug Development Historic Market Size by Region (2021-2026)
- 5.2.3 AI In Drug Development Forecasted Market Size by Region (2027-2032)
- 5.3 AI In Drug Development Market Dynamics
- 5.3.1 AI In Drug Development Industry Trends
- 5.3.2 AI In Drug Development Market Drivers
- 5.3.3 AI In Drug Development Market Challenges
- 5.3.4 AI In Drug Development Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top AI In Drug Development Players by Revenue
- 6.1.1 Global Top AI In Drug Development Players by Revenue (2021-2026)
- 6.1.2 Global AI In Drug Development Revenue Market Share by Players (2021-2026)
- 6.2 Global AI In Drug Development Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of AI In Drug Development Head Office and Area Served
- 6.4 Global AI In Drug Development Players, Product Type & Application
- 6.5 Global AI In Drug Development Manufacturers Established Date
- 6.6 Global AI In Drug Development Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America AI In Drug Development Market Size (2021-2032)
- 7.2 North America AI In Drug Development Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America AI In Drug Development Market Size by Country (2021-2026)
- 7.4 North America AI In Drug Development Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe AI In Drug Development Market Size (2021-2032)
- 8.2 Europe AI In Drug Development Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe AI In Drug Development Market Size by Country (2021-2026)
- 8.4 Europe AI In Drug Development Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific AI In Drug Development Market Size (2021-2032)
- 9.2 Asia-Pacific AI In Drug Development Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific AI In Drug Development Market Size by Country (2021-2026)
- 9.4 Asia-Pacific AI In Drug Development Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America AI In Drug Development Market Size (2021-2032)
- 10.2 South America AI In Drug Development Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America AI In Drug Development Market Size by Country (2021-2026)
- 10.4 South America AI In Drug Development Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa AI In Drug Development Market Size (2021-2032)
- 11.2 Middle East & Africa AI In Drug Development Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa AI In Drug Development Market Size by Country (2021-2026)
- 11.4 Middle East & Africa AI In Drug Development Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Pfizer
- 12.1.1 Pfizer Company Information
- 12.1.2 Pfizer Business Overview
- 12.1.3 Pfizer Revenue in AI In Drug Development Business (2021-2026)
- 12.1.4 Pfizer AI In Drug Development Product Portfolio
- 12.1.5 Pfizer Recent Developments
- 12.2 AstraZeneca
- 12.2.1 AstraZeneca Company Information
- 12.2.2 AstraZeneca Business Overview
- 12.2.3 AstraZeneca Revenue in AI In Drug Development Business (2021-2026)
- 12.2.4 AstraZeneca AI In Drug Development Product Portfolio
- 12.2.5 AstraZeneca Recent Developments
- 12.3 Johnson & Johnson
- 12.3.1 Johnson & Johnson Company Information
- 12.3.2 Johnson & Johnson Business Overview
- 12.3.3 Johnson & Johnson Revenue in AI In Drug Development Business (2021-2026)
- 12.3.4 Johnson & Johnson AI In Drug Development Product Portfolio
- 12.3.5 Johnson & Johnson Recent Developments
- 12.4 Novartis
- 12.4.1 Novartis Company Information
- 12.4.2 Novartis Business Overview
- 12.4.3 Novartis Revenue in AI In Drug Development Business (2021-2026)
- 12.4.4 Novartis AI In Drug Development Product Portfolio
- 12.4.5 Novartis Recent Developments
- 12.5 Sanofi
- 12.5.1 Sanofi Company Information
- 12.5.2 Sanofi Business Overview
- 12.5.3 Sanofi Revenue in AI In Drug Development Business (2021-2026)
- 12.5.4 Sanofi AI In Drug Development Product Portfolio
- 12.5.5 Sanofi Recent Developments
- 12.6 Roche
- 12.6.1 Roche Company Information
- 12.6.2 Roche Business Overview
- 12.6.3 Roche Revenue in AI In Drug Development Business (2021-2026)
- 12.6.4 Roche AI In Drug Development Product Portfolio
- 12.6.5 Roche Recent Developments
- 12.7 Insilico Medicine
- 12.7.1 Insilico Medicine Company Information
- 12.7.2 Insilico Medicine Business Overview
- 12.7.3 Insilico Medicine Revenue in AI In Drug Development Business (2021-2026)
- 12.7.4 Insilico Medicine AI In Drug Development Product Portfolio
- 12.7.5 Insilico Medicine Recent Developments
- 12.8 Exscientia
- 12.8.1 Exscientia Company Information
- 12.8.2 Exscientia Business Overview
- 12.8.3 Exscientia Revenue in AI In Drug Development Business (2021-2026)
- 12.8.4 Exscientia AI In Drug Development Product Portfolio
- 12.8.5 Exscientia Recent Developments
- 12.9 BenevolentAI
- 12.9.1 BenevolentAI Company Information
- 12.9.2 BenevolentAI Business Overview
- 12.9.3 BenevolentAI Revenue in AI In Drug Development Business (2021-2026)
- 12.9.4 BenevolentAI AI In Drug Development Product Portfolio
- 12.9.5 BenevolentAI Recent Developments
- 12.10 Recursion Pharmaceuticals
- 12.10.1 Recursion Pharmaceuticals Company Information
- 12.10.2 Recursion Pharmaceuticals Business Overview
- 12.10.3 Recursion Pharmaceuticals Revenue in AI In Drug Development Business (2021-2026)
- 12.10.4 Recursion Pharmaceuticals AI In Drug Development Product Portfolio
- 12.10.5 Recursion Pharmaceuticals Recent Developments
- 12.11 Atomwise
- 12.11.1 Atomwise Company Information
- 12.11.2 Atomwise Business Overview
- 12.11.3 Atomwise Revenue in AI In Drug Development Business (2021-2026)
- 12.11.4 Atomwise AI In Drug Development Product Portfolio
- 12.11.5 Atomwise Recent Developments
- 12.12 Isomorphic Labs
- 12.12.1 Isomorphic Labs Company Information
- 12.12.2 Isomorphic Labs Business Overview
- 12.12.3 Isomorphic Labs Revenue in AI In Drug Development Business (2021-2026)
- 12.12.4 Isomorphic Labs AI In Drug Development Product Portfolio
- 12.12.5 Isomorphic Labs Recent Developments
- 12.13 XtalPi
- 12.13.1 XtalPi Company Information
- 12.13.2 XtalPi Business Overview
- 12.13.3 XtalPi Revenue in AI In Drug Development Business (2021-2026)
- 12.13.4 XtalPi AI In Drug Development Product Portfolio
- 12.13.5 XtalPi Recent Developments
- 12.14 Deep Genomics
- 12.14.1 Deep Genomics Company Information
- 12.14.2 Deep Genomics Business Overview
- 12.14.3 Deep Genomics Revenue in AI In Drug Development Business (2021-2026)
- 12.14.4 Deep Genomics AI In Drug Development Product Portfolio
- 12.14.5 Deep Genomics Recent Developments
- 12.15 Relay Therapeutics
- 12.15.1 Relay Therapeutics Company Information
- 12.15.2 Relay Therapeutics Business Overview
- 12.15.3 Relay Therapeutics Revenue in AI In Drug Development Business (2021-2026)
- 12.15.4 Relay Therapeutics AI In Drug Development Product Portfolio
- 12.15.5 Relay Therapeutics Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst